ONO-8711 dicyclohexylamine|西域试剂

ONO-8711 dicyclohexylamine,98.09%

产品编号：Bellancom-12182A| 分子式：C₃₄H₅₃ClN₂O₄S| 分子量：621.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-12182A	￥1300.00	杭州北京（现货）
Bellancom-12182A	￥4100.00	杭州北京（现货）
Bellancom-12182A	￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

ONO-8711 dicyclohexylamine

产品介绍

ONO-8711 dicyclohexylamine 是一种有效的选择性竞争性 EP1 拮抗剂，对人和小鼠 EP1 的 K_i 值分别为 0.6 nM 和 1.7 nM。ONO-8711 dicyclohexylamine 有效降低结肠癌、乳腺癌和口腔癌小鼠模型的肿瘤发生率。

生物活性

ONO-8711 dicyclohexylamine is a selective and orally active EP1 competitive antagonist with K_i value of 0.6 nM and 1.7 nM for human and mouse EP1 respectively. ONO-8711 dicyclohexylamine effectively reduces tumor incidence and multiplicity in mouse models of colon, breast, and oral cancer.

体外研究

ONO-8711 (10 and 30 μM; 30 min) blocks the contractions induced by sulprostone in human pulmonary veins in a non-competitive manner.
ONO-8711 inhibits PGE₂-induced increase in cytosolic Ca²⁺ concentration with IC₅₀s of 0.21 μM, 0.05 μM, and 0.22 μM for the mouse, human, and rat receptors, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

ONO-8711 (400 or 800 p.p.m.; p.o.; for 20 weeks) suppresses cancer incidence and delays occurrence of breast tumors.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (induced breast cancer by gavage of 85 mg/kg PhIP (HY-118716) 4 times for 2 weeks)
Dosage:	400 or 800 p.p.m.
Administration:	p.o.; for 20 weeks
Result:	Did not induce any symptoms of toxicity at 800 p.p.m.. Delayed occurrence of breast tumors for 2 or 4 weeks at 400 or 800 p.p.m., respectively. Significantly suppressed cancer incidence compared with the control diet group at 800 p.p.m. (56% versus 79%, P < 0.05).

体内研究

ONO-8711 (400 or 800 p.p.m.; p.o.; for 20 weeks) suppresses cancer incidence and delays occurrence of breast tumors.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (induced breast cancer by gavage of 85 mg/kg PhIP (HY-118716) 4 times for 2 weeks)
Dosage:	400 or 800 p.p.m.
Administration:	p.o.; for 20 weeks
Result:	Did not induce any symptoms of toxicity at 800 p.p.m.. Delayed occurrence of breast tumors for 2 or 4 weeks at 400 or 800 p.p.m., respectively. Significantly suppressed cancer incidence compared with the control diet group at 800 p.p.m. (56% versus 79%, P < 0.05).

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (80.48 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6095 mL	8.0475 mL	16.0950 mL
5 mM	0.3219 mL	1.6095 mL	3.2190 mL
10 mM	0.1610 mL	0.8048 mL	1.6095 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献